COMPASS Pathways, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and has a $29.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ritu Baral has given his Buy rating due to a combination of factors related to COMP360’s differentiated clinical profile and commercial potential. She highlights that COMP360 has shown fast, meaningful, and long‑lasting antidepressant effects in treatment‑resistant depression, with patients typically needing only a few sessions per year, unlike competing options that require ongoing weekly dosing.
In her view, this durability, alongside a favorable safety profile and clear Phase 3 data, strongly supports a path to U.S. approval around 2027 and positions COMPASS as the leading psychedelic‑based mental health company. She also expects efficient rollout through existing interventional psychiatry clinics, believes reimbursement risks are manageable given payer‑relevant data, and models substantial peak U.S. revenue, all of which underpin her positive stance on the stock.
In another report released on March 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.